Publications by authors named "Takashi Hisai"
Article Synopsis
- The TACTICS-L trial studied the combination of transarterial chemoembolization (TACE) and lenvatinib (LEN) for treating unresectable intermediate-stage hepatocellular carcinoma (HCC), aiming to improve outcomes since recurrence is common after TACE alone.
- Patients with specific criteria were given LEN before and after TACE, with primary results showing a median progression-free survival of 28.0 months and high overall response rates (79% with 53% complete response 4 weeks post-TACE).
- The trial included 62 participants, mostly men aged around 72, and results indicated that combining LEN with TACE could be beneficial across different patient subgroups.
Article Synopsis
- E7130 is a new cancer treatment derived from norhalichondrin B, tested for safety and tolerability in a first-in-human trial with advanced solid tumor patients in Japan.
- The study involved escalating doses given intravenously in two different schedules (Q3W and Q2W), with safety monitored through adverse events, leading to the identification of maximum tolerated doses (MTDs).
- Results showed that all patients experienced treatment-related adverse events, with leukopenia being the most common; ultimately, E7130 at 480 μg/m Q3W was selected for further study based on promising biomarker responses.
This phase I study assessed the pharmacokinetic profile, safety and antitumor activity of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma. Bodyweight-based lenvatinib dosing was administered (patients <60 kg: 8 mg/day, n = 13; patients ≥60 kg: 12 mg/day, n = 12). Pharmacokinetic sampling was performed during the first cycle.
View Article and Find Full Text PDFBackground: Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor alpha, RET, and KIT. This phase 2, single-arm, open-label multicenter study evaluated lenvatinib in advanced hepatocellular carcinoma (HCC).
Methods: Patients with histologically/clinically confirmed advanced HCC who did not qualify for surgical resection or local therapies received lenvatinib at a dosage of 12 mg once daily (QD) in 28-day cycles.